Calliditas Therapeutics (CALT) announced that they have entered into an exclusive license agreement with Viatris (VTRS), to register and commercialize Nefecon, a specialty drug recently approved in Europe and the U.S. for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy, or IgAN, in Japan. Under the terms of the agreement, Calliditas is entitled receive an initial upfront payment of $20M upon signing and up to an additional $80M in pre-defined development and commercialization milestones. Viatris will also pay mid-teens percentage royalties on net sales. IgAN, also known as Berger’s disease, is a rare and serious progressive autoimmune disease in which up to 50% of patients end up at risk of developing end stage renal disease and thus requiring dialysis or a kidney transplant.
Published first on TheFly
